Search Results
Your search for s matches 6865 pages
Showing 2201 - 2250Lenvatinib in Recurrent or Metastatic Adenoid Cystic Carcinoma
In a single-center phase II study reported in the Journal of Clinical Oncology, Tchekmedyian et al found that the multitargeted tyrosine kinase inhibitor lenvatinib was active in progressive recurrent or metastatic adenoid cystic carcinoma. Study Details In the study, 32 evaluable patients at...
ASTRO Radiation Oncologist Workforce Study Shows Demographic Shifts
The newest study of America’s radiation oncologist workforce finds that gender and racial gaps have narrowed slightly, although persistent and growing geographic disparities point to a need for more equity in access to radiation therapy care. The survey found that fewer radiation oncologists...
American Cancer Society Report Finds Application of Cancer-Reducing Strategies in the United States Is Suboptimal
The latest edition of the American Cancer Society’s (ACS) review on recent cancer prevention and early detection efforts has found that although many strategies have been proven to reduce cancer risk, their application has been suboptimal in the United States, especially in socioeconomically...
Opioid-Related Hospitalizations Among Patients With Cancer in the United States
In a study reported in a research letter in JAMA Oncology, Chua et al found that opioid-related hospitalizations among American patients with cancer are rare, increasing at a very low rate, and consist mostly of hospitalization for nonheroin opioid poisoning. The study analyzed trends and risk...
FDA Expands Pembrolizumab Indication for NSCLC in First-Line Setting
Today, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the first-line treatment of patients with stage III non–small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or those with metastatic NSCLC....
ASCO Announces New Task Force to Address Rural Cancer Care Gap
Yesterday at the National Press Club in Washington, DC, ASCO announced a new task force aimed at reducing disparities and improving outcomes for patients and survivors of cancer who live in rural communities. The new Rural Cancer Care Task Force will identify opportunities to close the care gap and ...
ELCC 2019: Does Maintenance Immunotherapy Improve Survival in Patients With Advanced SCLC?
Maintenance immunotherapy did not improve survival in patients with extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study presented today by Owonikoko et al at the European Lung Cancer Congress 2019 (Abstract LBA1_PR). Around 60% to 70% of...
ELCC 2019: Immunotherapy in Elderly Patients With Advanced NSCLC
Two studies reported at the European Lung Cancer Congress (ELCC) 2019 provided new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non–small cell lung cancer (NSCLC). Although around half of all people newly diagnosed with NSCLC are elderly (Pallis ...
Lung Cancer Organizations Join Forces to Launch GO2 Foundation for Lung Cancer
Two nonprofit organizations serving the lung cancer community—the Bonnie J. Addario Lung Cancer Foundation (ALCF) and Lung Cancer Alliance (LCA)—have announced they are joining forces as the GO2 Foundation for Lung Cancer. With more than 3 decades of combined expertise, a...
Initiative to Improve Tobacco Cessation Efforts in a Radiation Oncology Department
In a study reported in the Journal of Oncology Practice, Singer et al found that a quality improvement initiative was successful in increasing a radiation oncology department’s efforts in encouraging patients with cancer to cease tobacco use prior to radiation therapy. As noted by the...
Researcher Supported by ASCO’s Conquer Cancer Foundation Earns Spot in Clinical Cancer Advances 2019 for Lymphoma Trial
THE WORK of nine researchers who have previously received funding from Conquer Cancer is featured in ASCO’s Clinical Cancer Advances 2019. Visit CONQUER.ORG/CCA for more details. Immunotherapy for Lymphoma AT THE University of Texas MD Anderson Cancer Center in Houston, Sattva S. Neelapu, MD, led...
Carson Leslie Foundation Joins Forces With ASCO’s Conquer Cancer Foundation to Fight Medulloblastoma
Carson Leslie was a kind, popular, lively teen who loved sports and spending time with his family and friends. He was a devoted student at The Covenant School of Dallas, where he was quarterback on the school’s football team, and he was an active member of Grace Bible Church. He shared a special...
AACR and Lung Cancer Initiative at Johnson & Johnson Announce Science Grant Recipients
The American Association for Cancer Research (AACR) and the Lung Cancer Initiative at Johnson & Johnson (LCI) recently announced the inaugural recipients of the AACR–Johnson & Johnson Lung Cancer Innovation Science Grants. The grants represent a new funding opportunity to support research...
Vaccine Plus Trastuzumab in Preventing Recurrence of HER2–Low-Expressing Breast Cancer
IN HIGH-RISK patients with breast cancer and low expression of HER2 (HER2 low), a peptide vaccine targeting HER2, combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), and given concurrently with trastuzumab, may help to prevent recurrence. Final analysis of a randomized phase...
Maitake Mushroom
GUEST EDITOR Integrative Oncology is guest edited by Jun J. Mao, MD, MSCE, Laurance S. Rockefeller Chair in Integrative Medicine and Chief of Integrative Medicine Service at Memorial Sloan Kettering Cancer Center, New York. The ASCO Post’s Integrative Oncology series is intended to...
Human Gene Therapy: Progress and Oversight
The early debate over the social and ethical implications of gene therapy led the National Institutes of Health (NIH) to establish the Recombinant DNA Advisory Committee in 1974. However, the risks of human gene therapies were largely unknown until 1999, when a patient died of a massive immune...
Photos From the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Arie S. Belldegrun, MD, FACS (right), receives the Keynote Award before delivering his lecture on “Progress in Cell Therapy: A Three-Decade Personal Journey.” Dr. Belldegrun is Surgical Director of the Genitourinary Oncology Department at the University of California, Los Angeles. The award was...
Advanced HER2-Positive Breast Cancer: All Eyes on These Novel Agents
NEW AGENTS for the treatment of advanced HER2-positive breast cancer should be coming soon to your clinic, according to Sara A. Hurvitz, MD, Director of the Breast Cancer Clinical Research Program and Associate Professor of Medicine at the David Geffen School of Medicine at the University of...
VISTA Checkpoint Implicated in Pancreatic Cancer Immunotherapy Resistance
Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers. A research team from The University of Texas MD Anderson Cancer Center...
Expert Point of View: Christopher L. Hallemeier, MD, and Andrew S. Kennedy, MD
Christopher L. Hallemeier, MD, Associate Professor in Radiation Oncology at the Mayo Clinic, Rochester, and Andrew S. Kennedy, MD, Physician in Chief of Radiation Oncology at Sarah Cannon, Nashville, and Director of Radiation Oncology Research, Sarah Cannon Research Institute, commented on the...
Study Finds Shorter Treatment Course for Rectal Cancer May Actually Improve Outcomes
In patients with locally advanced rectal cancer, the delivery of all radiotherapy and chemotherapy neoadjuvantly—with a shorter course of radiation—may improve the chance of complete response and downstaging over conventional treatment, according to investigators from Washington University, St....
Expert Point of View: William Kevin Kelly, DO
Formal discussant of the CheckMate 650 trial, William Kevin Kelly, DO, Professor of Medical Oncology at the Sidney Kimmel Cancer Center and Jefferson Health in Philadelphia, commented on the combination therapy’s toxicity. “The discontinuation of study drug was significant. An important issue is...
CDC Issues Clarification on Guideline for Prescribing Opioids for Chronic Pain in Patients With Cancer and Sickle Cell Disease
ASCO, the American Society of Hematology (ASH), and the National Comprehensive Cancer Network® (NCCN®) are pleased to acknowledge receipt of a key clarification from the Centers for Disease Control and Prevention (CDC) on prescribing opioids to manage pain from certain conditions. ...
Skin Cancer 2019: Small Study of Electrochemotherapy for Basal Cell Carcinomas in the Head and Neck Region
Increasing evidence is emerging about the effectiveness of electrochemotherapy in the treatment of basal cell carcinomas in the head and neck region. A study presented by Kis et al at the World Congress on Advanced Treatments and Technologies in Skin Cancer (Skin Cancer 2019) (Poster Board 6) aimed ...
American College of Physicians Issues Guidance Statement for Breast Cancer Screening in Average-Risk Women
Average-risk women between the ages of 50 and 74 who have no symptoms for breast cancer should undergo breast cancer screening with mammography every other year, the American College of Physicians (ACP) has recommended in a new evidence-based guidance statement published by Qaseem et al...
Trends in Neoadjuvant Therapy for Resectable Pancreatic Cancer
SEVERAL STUDIES at the 2019 Gastrointestinal Cancers Symposium evaluated the benefits of neoadjuvant treatment in patients with pancreatic cancer—and in patients deemed fully resectable, not just “borderline” resectable.1-3 Although the standard of care for resectable pancreatic ductal...
Conference Highlights From the 2019 Gastrointestinal and Genitourinary Cancers Symposiums
THIS YEAR saw a huge turnout and a large number of scientific abstracts presented at both the 2019 Gastrointestinal (GI) Cancers Symposium, held on January 17–19, and the 2019 Genitourinary (GU) Cancers Symposium, held on February 14–16, both in San Francisco. The GU Cancers Symposium attracted...
Preventive Medication Use in the Last Year of Life in Older Patients With Cancer
A new study reveals that preventive medications—such as those to lower blood pressure or cholesterol, or to protect bone health, among others—are commonly prescribed during the last year of life of older adults with cancer, even though they are unlikely to provide meaningful benefits....
FDA Expands Palbociclib Indication in HR-Positive, HER2-Negative Breast Cancer to Include Male Patients
Today, the U.S. Food and Drug Administration (FDA) extended the indication of palbociclib (Ibrance) capsules in combination with specific endocrine therapies for hormone receptor (HR)–positive, HER2-negative advanced or metastatic breast cancer to include male patients. “Today, we are...
Differences in Medical Cannabis Use in Patients With and Without Cancer
People with and without cancer are more likely, over time, to use a more potent form of medical marijuana with increasingly higher amounts of tetrahydrocannabinol (THC), a new study published by Kim et al in the Journal of Palliative Medicine has shown. “Although there is growing...
AACR 2019: Does Primary Tumor Surgery Increase Survival in Patients With Advanced HER2-Positive Breast Cancer?
Surgery was associated with higher survival rates for patients with HER2-positive stage IV breast cancer compared with those who did not undergo surgery, according to results presented by Mudgway et al at the American Association for Cancer Research (AACR) Annual Meeting (Abstract 4873). Between...
Racial Disparities in Matched Volunteer Stem Cell Donors
Although the pool of registered bone marrow donors has increased in recent years, a new study suggests that most patients of southern European and non-European descent are unlikely to have a suitable match if they need a bone marrow transplant. If an immediate registry search does not identify a...
AACR 2019: Higher BMI Before Age 50 May Increase Risk of Pancreatic Cancer
A higher body mass index (BMI) before age 50 may be more strongly associated with pancreatic cancer mortality risk than excess weight at older age, according to the results of a study presented by Jacobs et al at the American Association for Cancer Research (AACR) Annual Meeting 2019 (Abstract...
AACR 2019: Gilteritinib in Patients With FLT3-Mutated Acute Myeloid Leukemia
Treatment with the FLT3-targeted therapeutic gilteritinib improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring an FLT3 mutation compared with standard chemotherapy regimens, according to results from the phase III ADMIRAL trial presented by Perl et al at ...
AACR 2019: CD40 Antibody Combined With Chemotherapy in Advanced Pancreatic Cancer
An interim analysis of a small phase Ib study by O’Hara et al evaluating the CD40 agonistic monoclonal antibody APX005M in combination with gemcitabine and nab-paclitaxel with or without the programmed cell death protein 1 (PD-1) inhibitor nivolumab in untreated patients with metastatic...
AACR 2019: HER2-Targeted CAR T-Cell Therapy Plus Chemotherapy in Advanced Sarcoma
A small phase I study by Navai et al investigated a combination of lymphodepletion chemotherapy and HER2-specific chimeric antigen receptor (CAR) T-cell therapy for pediatric and adult patients with advanced HER2-positive sarcoma. The combination showed promising antitumor activity and was found to ...
FDA Oncology Center of Excellence Issues Annual Report
The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) has issued its 2018 Annual Report, including updates on regulatory reviews and initiatives, OCE programs, guidances, and more. Regulatory Reviews The OCE is tasked with clinical medical oncology reviews, irrespective...
FDA Pipeline: Mammography Policies, Designations for Leukemias and Myelodysplastic Syndrome
This week, the U.S. Food and Drug Administration (FDA) announced policy changes to modernize mammography policies and issued a Breakthrough Therapy designation, an Orphan Drug designation, and an investigational new drug application. FDA Advances Policy Changes to Modernize Mammography Services...
Lorlatinib in Advanced NSCLC With ALK Resistance Mutations
In a study reported in the Journal of Clinical Oncology, Shaw et al found that lorlatinib showed greater efficacy in patients with vs without anaplastic lymphoma kinase (ALK) resistance mutations among patients with advanced ALK-positive non–small cell lung cancer (NSCLC) in whom one or more...
Antoni Ribas, MD, PhD, Elected AACR President-Elect
The members of the American Association for Cancer Research (AACR) have elected Antoni Ribas, MD, PhD, as their President-Elect for 2019–2020. He will officially become President-Elect at the AACR Annual Meeting 2019 and he will assume the presidency in April 2020 at the AACR Annual Meeting...
ASCO Weighs in on Widespread Youth Tobacco Use: See the Latest National Youth Tobacco Survey Results
APPROXIMATELY 5 MILLION middle and high school students reported currently using a tobacco product, with over 3.6 million currently using e-cigarettes and about 2.5 million currently using a combustible tobacco product, according to the latest findings from the National Youth Tobacco Survey ...
Conquer Cancer Honors Researchers With Merit Awards
ASCO’S CONQUER CANCER FOUNDATION is pleased to announce the recipients of the Gastrointestinal Cancers, Genitourinary Cancers, and Clinical Immuno-Oncology Symposium Merit Awards. Conquer Cancer Merit Awards recognize oncology fellows’ and trainees’ high-quality research submitted in abstracts to...
Expert Point of View: Ajay K. Nooka, MD, MPH
THE ASCO POST asked Ajay K. Nooka, MD, MPH, Associate Professor, Division of Bone Marrow Transplant at Winship Cancer Institute, Emory University, to comment on studies involving daratumumab. “After the phase III SWOG S0777 trial demonstrated a survival benefit with a 3-drug induction regimen...
IMpassion130 Substudy: Atezolizumab/Nab-Paclitaxel Survival Benefits Limited to PD-L1–Positive Triple-Negative Breast Cancer
THE PHASE III IMpassion130 trial, first reported at the European Society for Medical Oncology (ESMO) 2018 Congress1 and published in The New England Journal of Medicine,2 found that the combination of front-line atezolizumab plus nab-paclitaxel significantly improved disease-free and overall...
Antibiotic Treatment Prior to Immune Checkpoint Inhibitor Therapy Shows Detrimental Effect on Response and Survival
USE OF ANTIBIOTICS prior to checkpoint blockade therapy may attenuate anticancer activity, according to data presented at the 2019 ASCO–Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium.1 Results of the multicenter study suggest that antibiotic therapy administered...
Expert Point of View: Emmanuel S. Antonarakis, MD
EMMANUEL S. ANTONARAKIS, MD, Associate Professor of Oncology, Johns Hopkins University, Baltimore, commented on the state of current knowledge about poly (ADP-ribose) polymerase (PARP) inhibitors in prostate cancer. “PARP inhibitors are definitely making inroads in the management of patients with...
Trastuzumab Biosimilar for HER2-Overexpressing Breast Cancer
ON DECEMBER 14, 2018, trastuzumab-pkrb (Herzuma) was approved as a biosimilar to trastuzumab for patients with HER2-overexpressing breast cancer.1 Trastuzumab-pkrb is indicated for adjuvant treatment of HER2-overexpressing breast cancer and metastatic HER2-overexpressing breast cancer.2 Health-care ...
New Data in Colorectal, Neuroendocrine, Gastric, and Hepatocellular Cancers
THE ANNUAL GASTROINTESTINAL CANCERS SYMPOSIUM took place earlier this year in San Francisco. In addition to important studies captured in our past few issues, The ASCO Post here briefly summarizes additional interesting studies. Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Colon Cancer...
Breast Density Assessment Variation by Screening Modality
Fewer women are assigned to a dense-breast category when evaluated with advanced mammographic screening technologies compared to standard digital mammography, according to a new study published by Gastounioti et al in Radiology. Density Assessment A woman’s breast density is assessed during ...
Genomic Testing Associated With Lower Health-Care Costs in Patients With High-Risk Breast Cancer
New research published by Dinan et al in JNCCN—Journal of the National Comprehensive Cancer Network provides evidence that genomic recurrence score testing using the 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast...
